drugset / Trial / NCT00002542
Tamoxifen in Treating Women With High-Risk Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer.
Timeline
- Start
- 1993-07-20
- Primary completion
- 2007-03-07
- Completion
- 2011-01-11
Publications
- Results Bramwell VHC, Pritchard KI, Tu D, et al.: How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). [Abstract] Breast Cancer Res Treat 106 (1): A-3055, 2007.
- Results Bramwell VH, Pritchard KI, Tu D, et al.: Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): interim results of NCIC-CTG MA.12. [Abstract] J Clin Oncol 25 (Suppl 18): A-547, 2007.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamoxifen | Small molecule | — | Oral |
| Background | Cyclophosphamide | Other / unclassified | — | Oral |
| Background | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Epirubicin | Small molecule | — | Intravenous |
| Background | Methotrexate | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | Intravenous |